INTS (Intensity Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 12, 2026)


INTS Intensity Therapeutics Inc INTS
28 GF Score
Price $4.78
! 1 Warning Sign
View Full Analysis

What is Intensity Therapeutics 5-Year Yield-on-Cost %?

Intensity Therapeutics INTS -2.05% 28 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates INTS with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 153 Biotechnology companies, Intensity Therapeutics ranks worse than 653594.12% on this metric.

Intensity Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Intensity Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



INTS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.7
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Intensity Therapeutics  (NAS:INTS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Intensity Therapeutics 5-Year Yield-on-Cost % Related Terms

INTS vs KPRX, PHIO, PBM: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Intensity Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intensity Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's 5-Year Yield-on-Cost % falls into.


INTS
28GF Score
Intensity Therapeutics Inc INTS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intensity Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Intensity Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Intensity Therapeutics (INTS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Intensity Therapeutics and its competitors. According to the industry distribution chart, Intensity Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry.
Is Intensity Therapeutics' 5-Year Yield-on-Cost % too high?
Intensity Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Intensity Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Intensity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Intensity Therapeutics' 5-Year Yield-on-Cost % compare to KPRX and PHIO?
According to the Biotechnology industry distribution chart, Intensity Therapeutics ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Intensity Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Intensity Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intensity Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intensity Therapeutics stock overvalued right now?
Intensity Therapeutics (INTS) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Intensity Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Intensity Therapeutics (INTS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intensity Therapeutics Business Description

Address 1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score

Get the complete analysis for INTS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.78
Price